title: Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer.
abstract: BACKGROUND
  We report a study of induction chemotherapy followed by concurrent chemoradiotherapy for stage IIIA/IIIB non-small cell lung cancer.
  
  
  METHODS
  Patients received two cycles of induction chemotherapy with cisplatin 100 mg/m(2) on day 1 and gemcitabine 1000 mg/m(2) on days 1, 8, and 15 of a 28-day cycle. If the disease was resectable [corrected] surgery was followed with two further cycles. If unresectable, patients received cisplatin 100 mg/m(2) day 1, 29 with 5-fluorouracil 1000 mg/m(2) per 24 h continuous infusion for 96 h on days 2-5 and days 30-33 of the radiotherapy administration. Radiation therapy consisted of 63 Gy, 35 fractions, 7 weeks.
  
  
  RESULTS
  Of 48 patients, 40% had a partial response to induction chemotherapy. Four of eleven patients with stage IIIA tumours had resectable disease. The remaining seven patients plus 37 with stage IIIB disease had chemoradiotherapy. Response at the completion of all therapy was 62% (IIIA 73%, IIIB 59%). For all patients the median survival was 15.3 months: 1 year and 3 years, 58% and 25%, respectively. Those with IIIB disease responding to induction chemotherapy had significantly superior survival to those that did not respond (37 months vs 11 months; P = 0.005). This remained significant from a landmark at 8 weeks after the start of treatment (P = 0.01).
  
  
  CONCLUSIONS
  These results are equivalent to other studies using induction chemotherapy prior to concurrent chemoradiotherapy. Response to induction chemotherapy may have major prognostic significance.
authors.affiliation: Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia. mjbyrne@cyllene.uwa.edu.au
authors.forename: M J
authors.initials: MJ
authors.lastname: Byrne
authors.forename: M
authors.initials: M
authors.lastname: Phillips
authors.forename: A
authors.initials: A
authors.lastname: Powell
authors.forename: F
authors.initials: F
authors.lastname: Cameron
authors.forename: D
authors.initials: D
authors.lastname: Joseph
authors.forename: N
authors.initials: N
authors.lastname: Spry
authors.forename: J
authors.initials: J
authors.lastname: Dewar
authors.forename: G
authors.initials: G
authors.lastname: Van Hazel
authors.forename: M
authors.initials: M
authors.lastname: Buck
authors.forename: H
authors.initials: H
authors.lastname: Lund
authors.forename: Y
authors.initials: Y
authors.lastname: De Melker
authors.forename: M
authors.initials: M
authors.lastname: Newman
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003841:Deoxycytidine; D002945:Cisplatin; D005472:Fluorouracil; D000093542:Gemcitabine